Boundless Bio (BOLD) shareholders elect directors, ratify KPMG auditor 鈥� 8-K

Q: Were the director nominees elected?

Yes. Christine Brennan, Ph.D. and Nancy Whiting, Pharm.D. were elected to serve until the 2028 annual meeting.

Q: How many votes supported the reappointment of KPMG LLP?

KPMG LLP received 17,791,309 votes For, with 47,807 Against and 100 Abstentions.

Q: How many broker non-votes were recorded for the director elections?

Each director item registered 3,540,518 broker non-votes.

Q: Did the Form 8-K disclose any financial results or strategic transactions?

No. The filing was limited to shareholder voting results; no earnings or transaction information was provided.

[8-K] Boundless Bio, Inc. Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.

Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.

No other matters were brought before shareholders and no additional material disclosures were made.

Insights

TL;DR: Routine annual-meeting votes; directors re-elected and KPMG confirmed鈥攏o material share-price impact expected.

The Form 8-K reports standard Item 5.07 results. Both Class I directors secured comfortable pluralities despite a meaningful number of withheld votes (鈮�34鈥�34.5%), which is not uncommon for emerging-growth biotech firms with concentrated ownership. Ratification of KPMG passed with 99.7% support, signalling continued investor confidence in financial controls. No compensation, strategic, or capital-allocation items were presented, and there are no implications for earnings or liquidity. From a governance and valuation perspective the filing is informational rather than catalytic, leaving the investment thesis unchanged.

06/23/2025 - 04:21 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 23, 2025

    

Boundless Bio, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-41989	83-0751369
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10955 Alexandria Way, Suite 100,
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (858) 766-9912

    

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	BOLD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 23, 2025 (the Meeting), two proposals were voted upon by the Company’s stockholders. The proposals are described in detail in the Company’s definitive proxy statement for the Meeting filed with the U.S. Securities and Exchange Commission on April 29, 2025. Below is a brief description of, and the final results of the votes for, each proposal.

Proposal 1: Each of the director nominees was elected as a Class I director to hold office until the Company’s 2028 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.


Nominee	Votes For		Votes Withheld		Broker Non‑Votes
Christine Brennan, Ph.D.		9,252,440		5,046,258		3,540,518
Nancy Whiting, Pharm.D.		9,758,214		4,540,484		3,540,518

Proposal 2: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 by the votes set forth below.


Votes For		Votes Against		Abstentions		Broker Non-Votes
	17,791,309		47,807		100		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			BOUNDLESS BIO, INC.

Date:	June 23, 2025	By:	/s/ Jessica Oien
			Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary

Source:

FAQ

What proposals were voted on at Boundless Bio's (BOLD) 2025 annual meeting?

Shareholders voted on the election of two Class I directors and the ratification of KPMG LLP as the 2025 independent auditor.

Were the director nominees elected?

Yes. Christine Brennan, Ph.D. and Nancy Whiting, Pharm.D. were elected to serve until the 2028 annual meeting.

How many votes supported the reappointment of KPMG LLP?

KPMG LLP received 17,791,309 votes For, with 47,807 Against and 100 Abstentions.

How many broker non-votes were recorded for the director elections?

Each director item registered 3,540,518 broker non-votes.

Did the Form 8-K disclose any financial results or strategic transactions?

No. The filing was limited to shareholder voting results; no earnings or transaction information was provided.

AG真人官方

[8-K] Boundless Bio, Inc. Reports Material Event

Insights

FORM 8-K

Item 5.07. Submission of Matters to a Vote of Security Holders.

FAQ

What proposals were voted on at Boundless Bio's (BOLD) 2025 annual meeting?

Were the director nominees elected?

How many votes supported the reappointment of KPMG LLP?

How many broker non-votes were recorded for the director elections?

Did the Form 8-K disclose any financial results or strategic transactions?

NASDAQ:BOLD

BOLD Rankings

BOLD Latest News

BOLD Latest SEC Filings

BOLD Stock Data

AG真人官方

Trending News

[8-K] Boundless Bio, Inc. Reports Material Event

Insights

Corporate Governance Expert neutral

FORM 8-K

Item 5.07. Submission of Matters to a Vote of Security Holders.

FAQ

What proposals were voted on at Boundless Bio's (BOLD) 2025 annual meeting?

Were the director nominees elected?

How many votes supported the reappointment of KPMG LLP?

How many broker non-votes were recorded for the director elections?

Did the Form 8-K disclose any financial results or strategic transactions?

NASDAQ:BOLD

BOLD Rankings

BOLD Latest News

BOLD Latest SEC Filings

BOLD Stock Data